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Objective: The purpose of this study was to investigate the effects of primary tumor location on the
survival of Chinese women with T1-2N0M0 breast cancer.
Methods: The clinical data of 1044 patients with stage T1-2N0M0 breast cancer who were treated from
1999 to 2007 were retrospectively analyzed. Patients were divided according to the primary tumor
location: upper-outer quadrant (UOQ), upper-inner quadrant (UIQ), lower-outer quadrant (LOQ), lower-
inner quadrant (LIQ), and nipple and central breast (central). The effect of primary tumor location on
recurrence-free survival (RFS) and overall survival (OS) were determined.
Results: The median age at diagnosis was 47 years. The tumor was located in the UOQ in 524 patients
(50.2%), the LOQ in 124 (11.9%), the UIQ in 229 (21.9%), the LIQ in 59 (5.7%), and centrally in 108 patients
(10.3%). The 5- and 10-year RFS and OS of the LIQ group were signiﬁcantly poorer than that of patients in
the other groups (RFS: 72.1% vs. 82.2e86.7%, P ¼ 0.041; OS: 73.6% vs. 85.3e89.1%, P ¼ 0.024). Multivariate
Cox analysis showed that primary tumor location in the LIQ was an independent prognostic factor for RFS
(hazard ratio [HR] ¼ 2.977; 95% conﬁdence interval [CI] 1.219e7.273; P ¼ 0.017) and OS (HR ¼ 2.949; 95%
CI 1.207e7.208; P ¼ 0.018).
Conclusion: Primary tumor location is an important prognostic factor for survival of Chinese womenwith
T1-2N0M0 breast cancer.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
With improvements of breast cancer screening techniques more
patients with breast cancer are diagnosed at an early stage, and
combined modality therapy has increased the survival rate [1]. The
10-year overall survival (OS) and recurrence-free survival (RFS) of
patients with stage T1-2N0M0 breast cancer have reached
approximately 90% and 80%, respectively [2,3]. However, some
patients with early breast cancer still have poor outcomes. It has
been shown that age, primary tumor size, histological grade,
endocrine receptor status, HER-2 expression, and axillary lymph45@hotmail.com (Z. He).
ted equally to this work.
by Elsevier Ltd. All rights reservednode metastasis are associated with the prognosis of patients with
breast cancer [4e6], and these factors are an important basis for
selecting adjuvant therapy [7]. However, patients with similar tu-
mor stages may have varied responses to treatment, suggesting
that other factors may play a decisive role in treatment response
and therapeutic outcome.
The primary tumor site is one of the main factors affecting
treatment choice and prognosis in gastric cancer. However, the
predictive value of primary tumor site in breast cancer is unclear.
Although many studies have suggested that primary tumor site is a
prognostic factors in patients with breast cancer, and patients with
tumors in the inner quadrant have a signiﬁcantly poorer prognosis
than patients with tumor in other quadrants [8e10], other studies
suggest that breast cancer survival is not related to the primary
tumor site. [11] Currently, there are no reports on the relationship
between primary tumor site and prognosis in Chinese womenwith.
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of the primary tumor site on the prognosis and survival of Chinese
women with stage T1-2N0M0 breast cancer.
2. Methods
2.1. Patients
The records of patients with breast cancer who were treated at
Sun Yat-Sen Cancer Center from January 1999 to January 2007were
retrospectively analyzed. Inclusion criteria were: 1) women with
pathologically conﬁrmed unilateral breast cancer; 2) post total
mastectomy and axillary lymph node dissection; 3) postoperative
pathological stage was T1-2N0M0 according to the 2009 UICC/AJCC
staging criteria; 4) complete surgical resection of the tumor and no
positive surgical margins; 5) complete estrogen receptor (ER),
progesterone receptor (PR), and HER2 results; 6) no preoperative
neoadjuvant chemotherapy or postoperative adjuvant
radiotherapy.
The study was approved by the ethics committee of Sun Yat-Sen
University Cancer Center. All patients provided written consent for
storage of their medical information in the hospital database and
for research use of this information.
2.2. Clinicopathologic factors and deﬁnition of tumor site
Patient clinical, pathological, and immunohistochemical factors
including age, menopausal status, pT stage, histological grade,
lymphovascular invasion, ER, PR, and HER2 status, and adjuvant
chemotherapy regimen were used to assess the risk of recurrence
and death. The primary tumor sitewas divided into the upper-outer
quadrant (UOQ), upper-inner quadrant (UIQ), lower-outer quadrant
(LOQ), lower-inner quadrant (LIQ), and central location including
the nipple and areola complex (central). ER- and PR-positivity was
deﬁned as more than 10% positive cells in immunohistochemical
staining. HER2-positivity was deﬁned as a 3þ immunohistochem-
ical staining result or 2þ immunohistochemical staining result
conﬁrmed by ﬂuorescent in situ hybridization (FISH).
2.3. Follow-up and survival endpoints
Postoperatively, patients were seen for follow-up once every 3e
6 months. The beginning of the follow-up was deﬁned as the ﬁrst
day after the initial diagnosis. RFS and OS were the primary end-
points of the study. The survival status of patients was obtained
through review of themedical records, phone call, or letter. RFS was
considered locoregional recurrence of disease and/or distant me-
tastases, and locoregional recurrence was conﬁrmed by patholog-
ical examination of a tissue specimen. Distant metastasis was
deﬁned as any relapse outside the locoregional recurrence area and
was conﬁrmed using two types of medical imaging methods (and
pathology assessment, if needed). Overall survival was deﬁned as
breast cancer-related deaths.
2.4. Statistical analysis
Categorical data were compared using the c2 test and Fisher’s
exact test. TheKaplaneMeiermethodwas used for calculation of the
survival rate and results displayed as a survival curve. Differences in
survival were examined using the log rank test. Univariate and
multivariate Cox regression model analysis were performed. Sig-
niﬁcant variables in univariate analysis (P< 0.05) were entered into
the multivariate regression model. A value of P < 0.05 was consid-
ered to indicate statistical signiﬁcance. SPSS 16.0 statistical software
was used to establish a database, and for all statistical analysis.3. Results
3.1. Patient clinicopathologic factors and treatment
A total of 1044 patients met the inclusion criteria, and were
included in the analysis. The patients were grouped according to
the primary tumor location. The tumor was located in the UOQ in
524 patients (50.2%), in the LOQ in 124 (11.9%), in the UIQ in 229
(21.9%), in the LIQ in 59 (5.7%), and in the central position in 108
patients (10.3%). Primary tumor location was not signiﬁcantly
associated with patient age, menopausal status, pT stage, histo-
logical grade, lymphovascular invasion, hormone receptor status,
HER2 status, and treatment (all, P > 0.05, Table 1).
All patients underwent total mastectomy and axillary lymph
node dissection after the diagnosis was made. The median number
of lymph nodes removed was 13 (range, 5e36). A total of 893 pa-
tients (82.7%) received adjuvant chemotherapy, with a median of 6
cycles (range,1e8 cycles), 736 patients received an anthracycline or
taxane regimen, and 127 patients with a cyclophosphamide,
methotrexate, and 5-ﬂuorouracil (CMF) regimen. No patients
received herceptin therapy. All hormone receptor-positive patients
received endocrine therapy. Premenopausal patients were treated
with tamoxifen, and postmenopausal women were treated with
tamoxifen or aromatase inhibitors. Clinicopathologic factors and
treatments are summarized in Table 1.
3.2. Survival and prognosis
The median follow-up duration was 68.1 months (range, 6e137
months), and 43 patients (4.1%) experienced local-regional recur-
rence including recurrence in the chest wall in 23 cases, in the
supraclavicular area in 14 cases, and in the axilla in 2 cases. Four
patients experienced recurrence at two or more locations. No
recurrence in the internal mammary lymph nodes occurred.
Distant metastases occurred in 110 cases (10.5%). The detail of the
distant metastases events were shown in Table 2. The 5-year and
10-year RFS were 89.1% and 82.6%, respectively. A total of 77 pa-
tients (7.4%) died of breast cancer, and the 5-year and 10-year OS
were 94.0% and 85.4%, respectively.
Univariate Cox regression model analysis of clinicopathologic
factors and showed that histological grade, primary tumor location,
ER status, and adjuvant chemotherapy regimen were prognostic
factors affecting RFS (P < 0.05). Histological grade, primary tumor
location, ER status, PR status and the adjuvant chemotherapy
regimen were prognostic factors affecting OS (P < 0.05) (Table 3).
The 5-year and 10-year RFS and OS of patients in the LIQ group
were signiﬁcantly worse than that of patients in other groups (RFS:
72.1% vs. 82.2e86.7%, P ¼ 0.041; OS: 73.6% vs. 85.3e89.1%,
P ¼ 0.024) (Table 4, Figs. 1 and 2).
In multivariate Cox regression model analysis, with inclusion of
the independent factors listed in univariate analysis, the location of
the tumor in LIQ was observed to be associated with hazards for
RFS and OS when compared with that of the other quadrant tumors
(RFS: HR 2.977, 95% CI 1.219e7.273, P ¼ 0.017; OS: HR 2.949, 95% CI
1.207e7.208, P ¼ 0.018). Additionally, histological grade and adju-
vant chemotherapy regimen also emerged as signiﬁcant indepen-
dent predictors with higher hazards for RFS and OS (P < 0.05)
(Table 5).
4. Discussion
In the present study, we retrospectively analyzed the data of
1044 Chinese women with stage T1-2N0M0 breast cancer who
underwent total mastectomy and explored the relationship be-
tween primary tumor site and prognosis. The results showed that
Table 1
Clinicopathologic characteristics of 1044 women with breast cancer according to tumor location.
Characteristics Total UOQ (%) LOQ (%) UIQ (%) LIQ (%) Central (%) P
Number 1044 524 (50.2) 124 (11.9) 229 (21.9) 59 (5.7) 108 (10.3)
Mean age (y) 47 48 47 47 45 48 0.286
Age (y)
<35 102 46 (8.8) 16 (12.9) 22 (9.6) 6 (10.2) 12 (11.1) 0.766
35e50 560 286 (54.6) 64 (51.6) 122 (53.3) 36 (61.0) 52 (48.1)
>50 382 192 (36.6) 44 (35.5) 85 (37.1) 17 (28.8) 44 (40.8)
Menopausal status
Premenopausal 658 328 (62.6) 80 (64.5) 148 (64.6) 41 (69.5) 61 (56.5) 0.485
Postmenopausal 386 196 (37.4) 44 (35.5) 81 (35.4) 18 (30.5) 47 (43.5)
Tumor stage
T1 456 221 (42.2) 47 (37.9) 107 (46.7) 31 (52.5) 50 (46.3) 0.266
T2 588 303 (57.8) 77 (62.1) 122 (53.3) 28 (47.5) 58 (53.7)
Histological grade
I 94 42 (8.0) 15 (12.1) 20 (8.7) 5 (8.5) 12 (11.1) 0.322
II 507 241 (46.0) 56 (45.2) 125 (54.6) 31 (52.5) 54 (50.0)
III 443 241 (46.0) 53 (42.7) 84 (36.7) 23 (39.0) 42 (38.9)
Lymphovascular invasion
Presence 75 34 (6.5) 9 (7.3) 17 (7.4) 5 (8.5) 10 (9.3) 0.110
Absence 754 362 (69.1) 94 (75.8) 180 (78.6) 43 (72.9) 75 (69.4)
Unknown 215 128 (24.4) 21 (16.9) 32 (14.0) 11 (18.6) 23 (21.3)
ER status
Negative 472 241 (56.0) 64 (51.6) 97 (42.4) 25 (42.4) 45 (41.7) 0.452
Positive 572 283 (54.0) 60 (48.4) 132 (57.6) 34 (57.6) 63 (58.3)
PR status
Negative 415 207 (39.5) 57 (46.0) 87 (38.0) 26 (44.1) 38 (35.2) 0.447
Positive 629 317 (60.5) 67 (54.0) 142 (62.0) 33 (55.9) 70 (64.8)
Her-2 status
Negative 754 379 (72.3) 81 (65.3) 167 (72.9) 45 (72.3) 82 (75.9) 0.377
Positive 290 145 (27.7) 43 (34.7) 62 (27.1) 14 (23.7) 26 (24.1)
Chemotherapya
CMF 127 67 (12.8) 15 (12.1) 22 (9.6) 4 (6.8) 19 (17.6) 0.207
Taxane and/or
anthracycline
736 375 (71.6) 94 (75.8) 162 (70.7) 38 (64.4) 67 (62.0)
UOQ, upper-outer quadrant; LOQ, lower-outer quadrant; UIQ, upper-inner quadrant; LIQ, lower-inner quadrant; ER, estrogen receptor; PR, progesterone receptor; HER2,
human epithelial growth factor receptor family 2; CMF, cyclophosphamide, methotrexate, and 5-ﬂuorouracil.
a Missing data.
S. Wu et al. / International Journal of Surgery 12 (2014) 394e398396
ORIGINAL RESEARCHthe primary tumor site was an important prognostic factor for
survival, and patients with tumors in the LIQ had poorer RFS and
OS.
Currently, the prognostic value of primary tumor site is still
controversial. Sarp et al. [8] found that an LIQ tumor locationwas an
independent prognostic factor for survival of patients with stage
T1N0M0 breast cancer. Colleoni et al. [12] found that axillary lymph
node metastasis occurred less frequently in patients with tumors
located within the inner quadrants than in patients with tumors
located in other quadrants, and patients with tumors located in the
LIQ had signiﬁcantly worse DFS and OS than patients with tumors
in other quadrants, in particular, much poorer than patients with
negative axillary lymph nodes. The results of the current study also
showed that the primary tumor site signiﬁcantly affected the
prognosis of patients with stage pT1-2N0M0 breast cancer. How-
ever, a study by Jayasinghe et al. [11] did not show that patients
with tumors located in the inner quadrants had a poorer prognosis
than patients with tumors in other quadrants. Sohn et al. [13]Table 2
Distribution of the ﬁrst event by speciﬁc distant metastases sites.
Distant metastases site n %
Isolated lung 23 20.9
Isolated bone 21 19.1
Isolated liver 14 12.7
Isolated soft tissue 8 7.3
Isolated brain 5 4.5
Multiple sites 39 35.5reported that the prognosis of patients with tumors in the UOQ
was better than that of patients with tumors in other quadrants, but
no comparison was made between the other quadrants. While the
results of studies examining the prognostic value of tumor site in
patients with early-stage breast cancer are inconsistent, the ﬁnd-
ings of our study are similar to those of prior research and indicate
that the primary tumor site is an important predictor of survival in
Chinese female patients with breast cancer, and may have value in
guiding adjuvant treatment.
It is commonly believed that potential internal mammary lymph
node metastasis is a reason that the prognosis of patients with
tumors in the inner quadrants is poorer than that of patients with
tumors in other quadrants [8e10]. However, a phase III study by
Hennequin et al. [14] with 10-year follow-up did not ﬁnd any value
of radiation therapy in patients with negative axillary lymph nodes.
In addition, Veronesi et al. [15] found that internal mammary
lymph node dissection was not associated with improved survival.
The recurrence rate of breast cancer in the internal mammary
lymph nodes is very low (<5%) [16], which is a likely reason no
recurrence in the internal mammary lymph nodes was noted in the
current study. The aforementioned studies did not show a beneﬁt
to the local treatment of internal mammary lymph nodes, leading
to the question of whether strengthened systemic therapy is
beneﬁcial or not.
Chen et al. [17] found that in stage N0 breast cancer patients,
positive internal mammary lymph nodes occurred more frequently
with inner quadrant tumors (7e20%) than in lateral tumors (3e
13%) or medial tumors (0e12%). Currently, there are very few
studies examining adjuvant chemotherapy in patients with stage
Table 3
Univariate cox analyses of recurrence-free survival and overall survival.
Characteristics RFS OS
HR 95% (CI) P HR 95% (CI) P
Age (y)
<35 1 1
35e50 0.813 0.465e1.420 0.467 0.712 0.344e1.475 0.361
>50 0.716 0.395e1.296 0.270 0.888 0.421e1.872 0.756
Menopausal status
Premenopausal 1 1
Postmenopausal 0.815 0.560e1.188 0.287 1.127 0.713e1.783 0.609
Tumor stage
T1 1 1
T2 1.435 0.996e2.068 0.053 1.32 0.833e2.097 0.237
Histological grade
IeII 1 1
III 3.385 1.496e7.660 0.003* 4.182 1.198e14.594 0.025*
Lymphovascular invasion
Absence 1 1
Presence 1.523 0.554e4.188 0.415 1.133 0.348e3.684 0.836
ER status
Negative 1 1
Positive 0.659 0.463e0.937 0.020* 0.620 0.395e0.973 0.038*
PR status
Negative 1 1
Positive 0.75 0.527e1.066 0.109 0.554 0.354e0.867 0.010*
Her-2 status
Negative 1 1
Positive 1.083 0.735e1.595 0.688 1.412 0.880e2.266 0.153
Tumor location
UOQ 1 1
LOQ 1.049 0.573e1.921 0.876 1.074 0.497e2.324 0.855
UIQ 1.319 0.853e2.039 0.213 1.204 0.679e2.133 0.525
LIQ 2.403 1.336e4.322 0.003* 3.206 1.620e6.341 0.001*
Central 0.988 0.517e1.887 0.970 0.852 0.358e2.030 0.717
Chemotherapy
CMF 1 1
Taxane and/or
anthracycline
0.519 0.337e0.799 0.003* 0.514 0.293e0.904 0.021*
RFS, recurrence-free survival; OS, overall survival; UOQ, upper-outer quadrant; LOQ,
lower-outer quadrant; UIQ, upper-inner quadrant; LIQ, lower-inner quadrant; ER,
estrogen receptor; PR, progesterone receptor; Her-2, human epithelial growth
factor receptor family 2; CMF, cyclophosphamide, methotrexate, and 5-ﬂuorouracil;
HR, hazard ratio; CI, conﬁdence interval.
*P < 0.05 indicates a signiﬁcant difference.
Table 5
Multivariate cox analysis of recurrence-free survival and overall survival.
Characteristics RFS OS
HR 95% CI P HR 95% CI P
ER status
Negative 1 1
Positive 0.663 0.395e1.113 0.120 0.811 0.422e1.558 0.529
PR status
Negative e e e 1
Positive e e e 0.717 0.377e1.363 0.310
Histological grade
IeII 1 1
III 2.006 1.102e3.652 0.023* 1.977 1.084e3.605 0.026*
Tumor location
UOQ 1 1
LOQ 1.194 0.518e2.748 0.677 1.178 0.512e2.712 0.700
UIQ 1.421 0.742e2.72 0.289 1.399 0.730e2.682 0.311
LIQ 2.977 1.219e7.273 0.017* 2.949 1.207e7.208 0.018*
Central 1.316 0.541e3.204 0.545 1.310 0.538e3.189 0.551
Chemotherapy
CMF 1 1
Taxane and/or
anthracycline
0.567 0.317e1.012 0.055 0.558 0.312e0.998 0.049*
RFS, recurrence-free survival; OS, overall survival; UOQ, upper-outer quadrant; LOQ,
lower-outer quadrant; UIQ, upper-inner quadrant; LIQ, lower-inner quadrant; HR,
hazard ratio; CI, conﬁdence interval; CMF, cyclophosphamide, methotrexate, and 5-
ﬂuorouracil.
*P < 0.05 indicates a signiﬁcant difference.
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tients underwent chemotherapy and it was found that patients
treated with an anthracycline and taxane regimen had a better
prognosis. In recent years, great progress has been made in the
systemic adjuvant treatment of breast cancer including anthracy-
clines, taxanes, endocrine therapy, and trastuzumab [18e21]. If
adjuvant systemic therapy can eliminate potential internal mam-
mary lymph node metastasis, it could improve local control and
reduce distant metastasis.
With greater understanding of the biological behavior of tu-
mors, more prognostic factors have been included in tumor staging.Table 4
Recurrence-free survival and overall survival according to tumor location.
Tumor
location
RFS OS
5-year (%) 10-year (%) P 5-year (%) 10-year (%) P
UOQ 90.8 83.3 0.041* 94.0 89.1 0.024*
LOQ 92.6 82.5 96.2 85.3
UIQ 86.7 82.2 94.2 86.4
LIQ 76.6 72.1 84.9 73.6
Central 89.7 86.7 96.9 86.7
RFS, recurrence-free survival; OS, overall survival; UOQ, upper-outer quadrant; LOQ,
lower-outer quadrant; UIQ, upper-inner quadrant; LIQ, lower-inner quadrant.
*P < 0.05 indicates a signiﬁcant difference.For example, the 7th edition of Esophageal Cancer UICC/AJCC
staging includes the primary site in the staging criteria [22].
Currently, staging of breast cancer is primarily based on primary
tumor size and lymph node status. The results of the present study
suggest that is necessary to further examine whether primary tu-
mor site should be included in UICC/AJCC staging of breast cancer to
better predict prognosis and guide the selection of adjuvant
treatment.
This study has some limitations that should be considered. First,
the study was retrospective and the number of patients with tu-
mors in the LIQ was small. Internal mammary lymph node
dissection or special imaging examinations were not performed,
and thus the presence of internal mammary lymph nodemetastasis
cannot be determined. HER2-positive patients did not undergo
herceptin therapy, and it is unclear whether targeted therapy
would have results in different outcomes.Fig. 1. KaplaneMeier curves of recurrence-free survival according to tumor location.
Fig. 2. KaplaneMeier curves of overall survival according to tumor location.
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In conclusion, the results of this study showed that primary
tumor site is an important prognostic factor of survival for Chinese
women with stage T1-2N0M0 breast cancer after mastectomy.Ethical approval
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